GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Gland Pharma Ltd
Gland Pharma Reappoints Independent Director Mr. Udo Johannes Vetter for 5 Years
MANAGEMENT ● No Immediate Change LOW RISK
📅 Filed on BSE: 15 Jun 2026, 04:45 PM IST  ·  BSE ID: bc78311d-fb37-425a-b19c-aa58121acf64
View Original BSE Filing (PDF)
💡
In Simple Terms
Gland Pharma's board has decided to keep an independent director for another five years, pending shareholder vote.
🤖 AI Summary
  • Mr. Udo Johannes Vetter reappointed Independent Director for second five-year term.
  • Reappointment effective July 21, 2026, through July 20, 2031.
  • Board decision made during meeting held on Monday, June 15, 2026.
  • Requires member approval under Regulations 17(1A) and 25(2A) of Listing Regulations.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Director DIN
00707474
Reappointment Term Start Date
July 21, 2026
Reappointment Term End Date
July 20, 2031
🏢 How This Affects the Company
⚠️
Risk Impact
The reappointment of an experienced independent director contributes to corporate governance stability, potentially mitigating governance-related risks.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the reappointment of Mr. Udo Johannes Vetter.
👤
Who Is Affected
All shareholders are affected by board composition decisions, which require their approval for independent director reappointments.
🔍
Management Signal
The Board's decision indicates a focus on maintaining experienced independent oversight and governance stability.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shareholder meeting notice for director reappointment vote.
Outcome of the shareholder vote on director reappointment.
Future board meeting minutes detailing director responsibilities.
LOW RISK Standard management change event requiring shareholder approval, with no inherent financial risks.
💡 Investor Takeaway
Gland Pharma Board reappointed Mr. Udo Johannes Vetter as Independent Director for a second five-year term, effective July 21, 2026, subject to member approval.
⚖️ Strengths & Concerns

✅ Positives

  • Continuity in independent directorship ensures consistent governance oversight and strategic guidance.
  • Reappointment for a full five-year term signals confidence in the director's ongoing contribution.
📅 Company Track Record
Gland Pharma has previously announced reappointments for Ms. Naina Lal Kidwai as Independent Director, indicating a pattern of board continuity.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
Who has been reappointed as an Independent Director at Gland Pharma?
Mr. Udo Johannes Vetter has been reappointed as an Independent Director at Gland Pharma.
What is the term for Mr. Udo Johannes Vetter's reappointment at Gland Pharma?
His reappointment is for a second term of five consecutive years, effective from July 21, 2026, to July 20, 2031.
When was the Gland Pharma Board meeting held for this decision?
The Gland Pharma Board meeting was held on Monday, June 15, 2026.
What shareholder approval is required for this reappointment?
Member approval is required under Regulation 17(1A) and 25(2A) of the Listing Regulations.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.